MedPath

Goserelin

Generic Name
Goserelin
Brand Names
Zoladex
Drug Type
Small Molecule
Chemical Formula
C59H84N18O14
CAS Number
65807-02-5
Unique Ingredient Identifier
0F65R8P09N
Background

Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Indication

Goserelin is indicated for:

Associated Conditions
Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
Associated Therapies
Palliative Treatment

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2009-04-20
Last Posted Date
2013-11-13
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
182
Registration Number
NCT00884273
Locations
🇮🇹

Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy

🇧🇪

Institut Jules Bordet, Bruxelles, Belgium

🇫🇮

KYS/kirurgian klin (Kuopio), Kuopio, Finland

and more 43 locations

Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy

Phase 4
Completed
Conditions
Spinobulbar Muscular Atrophy
Kennedy's Disease
First Posted Date
2009-02-26
Last Posted Date
2015-05-21
Lead Sponsor
Ramathibodi Hospital
Target Recruit Count
10
Registration Number
NCT00851461
Locations
🇹🇭

Medical Genetics and Molecular Medicine Unit,, Department of Medicine, Ramathibodi Hospital, Bangkok, Thailand

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2009-02-02
Last Posted Date
2012-10-04
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
246
Registration Number
NCT00833248
Locations
🇬🇧

Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom

🇫🇷

Clinique du Parc, Toulouse, France

🇫🇷

Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France

and more 63 locations

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Phase 3
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2009-01-28
Last Posted Date
2013-11-11
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
42
Registration Number
NCT00831233
Locations
🇪🇸

Fundación Puigvert, Barcelona, Spain

🇪🇸

Fundacion Hospital Alcorcón, Alcorcon, Spain

🇪🇸

Hospital de Basurto, Bilbao (Bizkaia), Spain

and more 29 locations

Zoladex Plus Tamoxifen in Breast Cancer

Not Applicable
Completed
Conditions
Mammography
Estrogen
Lipemia
Endometrium
Ultrasonography
Interventions
First Posted Date
2009-01-22
Last Posted Date
2011-08-08
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
100
Registration Number
NCT00827307
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Phase 2
Withdrawn
Conditions
Prostate Cancer
Interventions
Biological: GVAX prostate cancer vaccine
Drug: bicalutamide
Drug: goserelin
Drug: leuprolide acetate
First Posted Date
2008-10-10
Last Posted Date
2023-05-25
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT00771017

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2008-10-09
Last Posted Date
2017-03-29
Lead Sponsor
University of Washington
Target Recruit Count
29
Registration Number
NCT00769795
Locations
🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

🇺🇸

Virginia Mason Medical Center, Seattle, Washington, United States

🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Phase 3
Terminated
Conditions
Prostate Cancer
Interventions
Drug: bicalutamide
Drug: buserelin
Drug: flutamide
Drug: goserelin
Drug: leuprolide acetate
Procedure: neoadjuvant therapy
Procedure: quality-of-life assessment
Radiation: radiation therapy
Drug: Docetaxel
First Posted Date
2008-04-02
Last Posted Date
2023-08-04
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
48
Registration Number
NCT00651326
Locations
🇨🇦

McGill University - Dept. Oncology, Montreal, Canada

🇨🇦

Tom Baker Cancer Centre, Calgary, Canada

🇨🇦

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada

and more 10 locations

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2008-03-07
Last Posted Date
2015-01-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
19
Registration Number
NCT00631527
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

Phase 2
Completed
Conditions
Stage III Prostate Cancer
Prostate Adenocarcinoma
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Interventions
Drug: Bicalutamide
Drug: Goserelin Acetate
Other: Laboratory Biomarker Analysis
Drug: Leuprolide Acetate
Procedure: Therapeutic Conventional Surgery
Drug: Vorinostat
First Posted Date
2008-01-09
Last Posted Date
2017-10-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT00589472
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

UCSF Medical Center-Parnassus, San Francisco, California, United States

and more 12 locations
© Copyright 2025. All Rights Reserved by MedPath